Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TS 161

Next Previous
Search
Drug Profile

TS 161

Alternative Names: TS-161

Latest Information Update: 02 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taisho Pharmaceutical
  • Developer National Institute of Mental Health; Taisho Pharmaceutical
  • Class Antidepressants
  • Mechanism of Action Metabotropic glutamate receptor 2 antagonists; Metabotropic glutamate receptor 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder
  • No development reported Depressive disorders

Most Recent Events

  • 23 May 2024 National Institute of Mental Health completes a phase II trial in Major depressive disorder (Treatment resistant) in USA (PO) (NCT04821271)
  • 28 May 2023 No recent reports of development identified for preclinical development in Depressive disorders in Japan (PO, Capsule)
  • 28 Jul 2022 No recent reports of development identified for phase-I development in Depressive disorders(In volunteers) in USA (PO, Capsule)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top